Yes, I would be surprised if they were looking to partner the CLBP in USA with anyone apart from Gregory / SurgeCentre. With regards to heart would any partner want to be part of the upcoming FDA meeting. What seemed new was reference to 3D manufacturing, it would be great to have that funded and in place prior to the next Phase III for heart, so any potency assays, manufacturing inspections and results were with 3D in place.
I appreciate the immediate need for funds to stay afloat and delays with “shortly” but good to see target milestones for the next 12 months.
Ann: CEO Presentation to 2023 Annual General Meeting, page-7
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |